Andrea V.
- Country
- Italy
- Department
- UOC Ematologia
Research Overview
- Phase 2a Study of Tafasitamab in Adults with Primary Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia
- Phase 2 Study of Emavusertib and Zanubrutinib in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies
- Phase 3 Study of BGB-11417 plus Zanubrutinib versus Venetoclax plus Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia
Data & Insights
Has run more than one trial at 100 of 298 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular focus on developing innovative therapeutic approaches for both previously untreated and treated patients.
- Treatment optimization strategies
- Novel combination therapies
- Personalized treatment approaches
The investigator explores customized treatment regimens to enhance patient outcomes in hematologic conditions.
Autoimmune Complications
Research interests extend to the management of autoimmune hemolytic anemia (AIHA) in the context of lymphoid malignancies, particularly investigating targeted therapeutic interventions.
- AIHA treatment strategies
- CLL-associated autoimmune disorders
- Targeted therapy applications
The investigator studies the interconnection between autoimmune complications and blood cancers.
Advanced Therapeutics
Focus areas include the evaluation of novel therapeutic agents and their combinations, particularly in the context of B-cell disorders and related conditions.
- Innovative drug development
- Treatment response assessment
- Clinical outcomes evaluation
The investigator examines emerging treatments for hematologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.